ProChimia Surfaces is one of the nine consortium members of the Horizon 2020 project entitled “Nanofacturing - The Development of Medium- and Large-Scale Sustainable Manufacturing Process Platforms for Clinically Compliant Solid Core Nanopharmaceuticals” (grant agreement no. 646364). The project is a step ahead for the GMP process development and manufacturing of nanopharmacueticals, aimed at the efficacious and cost effective manufacture of gold core nanoparticles coupled with APIs for clinical use and successful administration in humans both clinical and ultimately commercial scale.

The “Nanofacturing” project is being coordinated by Midatech Pharma España SL (Spain) and project consortium comprises partners throughout Europe, specifically:

• Centre for BioNano Interactions (CBNI) National University of Ireland

• IFOM, Fondazione Istituto FIRC di Oncologia Molecolare (Italy)

• Ecole Polytechnique Federale de Lausanne (Switzerland)

• Midatech Pharma España SL (Spain)

• Midatech LTD (UK)

• Galchimia SA(Spain)

• Applus+ Laboratories, part of LGAI TECHNOLOGICAL CENTER SA(Spain)

• CPI- Centre for Process Innovation (UK)

• ProChimia Surfaces (Poland)

Out of the list the first three organizations are long term, valued ProChimia customers.

The Nanofacturing consortium benefits from the multidisciplinary expertise of its partners including state-of-the-art nanoparticle characterization.

During the 4-year project ProChimia’s specialists contribute to the development of the optimised and pharma-industry applicable process of thiolated ligands synthesis for gold nanoparticle construction: a key component of Midatech’s GNP technology.